Free Trial
NASDAQ:LONA

Athira Pharma Q1 2026 Earnings Results & Report

Athira Pharma logo
$3.23 -0.24 (-6.92%)
As of 03:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Athira Pharma reported Q1 2026 earnings on May 7, 2026. The company reported EPS of -$1.73.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Athira Pharma EPS Results

Actual EPS
-$1.73
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Athira Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Athira Pharma Q1 2026 Earnings FAQ

Athira Pharma (NASDAQ:LONA) reported earnings of -$1.73 per share for Q1 2026. The report was announced on Thursday, May 7, 2026.

Athira Pharma Earnings Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Athira Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email.

About Athira Pharma

Athira Pharma (NASDAQ:LONA) is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair.

The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis. These were development-stage candidates, not approved medicines.

Athira was founded in 2011 and advanced its programs through clinical research. Fosgonimeton did not meet the primary endpoints in a Phase 3 Alzheimer’s disease study, and the company subsequently reassessed its development plans.

View Athira Pharma Profile